The developers of Russia's leading COVID-19 vaccine candidate say it is 92% effective in preventing infection. The already-registered vaccine is currently in phase three of clinical trials and mass vaccination is expected in a matter of weeks. Julia Chapman has more.
IN: 16,000 trial participants....
OUT: SOC
DUR: 0:45
http://www.fsnradionews.com/feeds/1111SputnikV-jc.mp3
IN: 16,000 trial participants....
OUT: SOC
DUR: 0:45
http://www.fsnradionews.com/feeds/1111SputnikV-jc.mp3